ARTICLE | Deals
Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak
June 22, 2020 12:03 PM UTC
Codiak is extending its exosome platform to AAVs by partnering with Sarepta to overcome two major obstacles for nucleic acid therapies: tissue-targeting and repeat dosing.
The resulting products would be vectors within vectors, with multiple AAVs encapsulated by human cell-derived exosomes that direct them to muscle tissues while hiding them from the immune system. Once inside cells, the AAVs would mediate genomic integration of therapeutic nucleic acid cargo...